English
简体中文
Total: £ 56.28
Published Date: 2025-10-08 | Pages: 140 | Tables: 134 | Medical Care
The global Alzheimer's Disease Diagnosis market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
The Alzheimer's Disease Diagnosis market encompasses the tools, technologies, and services used to detect and diagnose Alzheimer's disease, a progressive neurodegenerative disorder. This market includes diagnostic methods such as imaging techniques (like PET, MRI, and CT scans), biomarker testing (blood, cerebrospinal fluid, and genetic testing), cognitive assessment tools, and novel diagnostic solutions like digital health tools and AI-based diagnostics. The growing prevalence of Alzheimer’s, increasing awareness of early detection, and advancements in diagnostic technologies are driving market growth. Pharmaceutical companies, research institutions, and healthcare providers play key roles in expanding diagnostic options. However, challenges such as the high cost of advanced diagnostic tools and limited access to specialized testing in certain regions can restrain the market’s growth. The Alzheimer's Disease Diagnosis market is critical for facilitating early and accurate diagnosis, which can improve patient management and outcomes.
From a downstream perspective, Clinical Diagnosis accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Alzheimer's Disease Diagnosis leading manufacturers including Roche, Quanterix, Quest Diagnostics, C₂N Diagnostics, Fujirebio, Diadem, Labcorp, Neurocode, Cognitact, EUROIMMUN Medical Diagnostics, etc., dominate supply; the top five capture approximately % of global revenue, with Roche leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Alzheimer's Disease Diagnosis market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Roche
Quanterix
Quest Diagnostics
C₂N Diagnostics
Fujirebio
Diadem
Labcorp
Neurocode
Cognitact
EUROIMMUN Medical Diagnostics
Vazyme International
KingMed Diagnostics
Hoyotek
Carrier Biomed
Segment by Type
Neuroimaging Examination
Cerebrospinal Fluid Examination
Peripheral Blood Antibody Examination
Others
Segment by Application
Clinical Diagnosis
Research
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Alzheimer's Disease Diagnosis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Alzheimer's Disease Diagnosis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Alzheimer's Disease Diagnosis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Neuroimaging Examination
1.2.3 Cerebrospinal Fluid Examination
1.2.4 Peripheral Blood Antibody Examination
1.2.5 Others
1.3 Market Segmentation by Application
1.3.1 Global Alzheimer's Disease Diagnosis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinical Diagnosis
1.3.3 Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Alzheimer's Disease Diagnosis Revenue Estimates and Forecasts 2020-2031
2.2 Global Alzheimer's Disease Diagnosis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Alzheimer's Disease Diagnosis Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Alzheimer's Disease Diagnosis Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Neuroimaging Examination Market Size by Players
3.3.2 Cerebrospinal Fluid Examination Market Size by Players
3.3.3 Peripheral Blood Antibody Examination Market Size by Players
3.3.4 Others Market Size by Players
3.4 Global Alzheimer's Disease Diagnosis Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Alzheimer's Disease Diagnosis Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Alzheimer's Disease Diagnosis Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Alzheimer's Disease Diagnosis Market Size by Type (2020-2031)
6.4 North America Alzheimer's Disease Diagnosis Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Alzheimer's Disease Diagnosis Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Alzheimer's Disease Diagnosis Market Size by Type (2020-2031)
7.4 Europe Alzheimer's Disease Diagnosis Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Alzheimer's Disease Diagnosis Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Alzheimer's Disease Diagnosis Market Size by Type (2020-2031)
8.4 Asia-Pacific Alzheimer's Disease Diagnosis Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Alzheimer's Disease Diagnosis Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Alzheimer's Disease Diagnosis Market Size by Type (2020-2031)
9.4 Central and South America Alzheimer's Disease Diagnosis Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Alzheimer's Disease Diagnosis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Alzheimer's Disease Diagnosis Market Size by Type (2020-2031)
10.4 Middle East and Africa Alzheimer's Disease Diagnosis Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Alzheimer's Disease Diagnosis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Business Overview
11.1.3 Roche Alzheimer's Disease Diagnosis Product Features and Attributes
11.1.4 Roche Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.1.5 Roche Alzheimer's Disease Diagnosis Revenue by Product in 2024
11.1.6 Roche Alzheimer's Disease Diagnosis Revenue by Application in 2024
11.1.7 Roche Alzheimer's Disease Diagnosis Revenue by Geographic Area in 2024
11.1.8 Roche Alzheimer's Disease Diagnosis SWOT Analysis
11.1.9 Roche Recent Developments
11.2 Quanterix
11.2.1 Quanterix Corporation Information
11.2.2 Quanterix Business Overview
11.2.3 Quanterix Alzheimer's Disease Diagnosis Product Features and Attributes
11.2.4 Quanterix Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.2.5 Quanterix Alzheimer's Disease Diagnosis Revenue by Product in 2024
11.2.6 Quanterix Alzheimer's Disease Diagnosis Revenue by Application in 2024
11.2.7 Quanterix Alzheimer's Disease Diagnosis Revenue by Geographic Area in 2024
11.2.8 Quanterix Alzheimer's Disease Diagnosis SWOT Analysis
11.2.9 Quanterix Recent Developments
11.3 Quest Diagnostics
11.3.1 Quest Diagnostics Corporation Information
11.3.2 Quest Diagnostics Business Overview
11.3.3 Quest Diagnostics Alzheimer's Disease Diagnosis Product Features and Attributes
11.3.4 Quest Diagnostics Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.3.5 Quest Diagnostics Alzheimer's Disease Diagnosis Revenue by Product in 2024
11.3.6 Quest Diagnostics Alzheimer's Disease Diagnosis Revenue by Application in 2024
11.3.7 Quest Diagnostics Alzheimer's Disease Diagnosis Revenue by Geographic Area in 2024
11.3.8 Quest Diagnostics Alzheimer's Disease Diagnosis SWOT Analysis
11.3.9 Quest Diagnostics Recent Developments
11.4 C₂N Diagnostics
11.4.1 C₂N Diagnostics Corporation Information
11.4.2 C₂N Diagnostics Business Overview
11.4.3 C₂N Diagnostics Alzheimer's Disease Diagnosis Product Features and Attributes
11.4.4 C₂N Diagnostics Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.4.5 C₂N Diagnostics Alzheimer's Disease Diagnosis Revenue by Product in 2024
11.4.6 C₂N Diagnostics Alzheimer's Disease Diagnosis Revenue by Application in 2024
11.4.7 C₂N Diagnostics Alzheimer's Disease Diagnosis Revenue by Geographic Area in 2024
11.4.8 C₂N Diagnostics Alzheimer's Disease Diagnosis SWOT Analysis
11.4.9 C₂N Diagnostics Recent Developments
11.5 Fujirebio
11.5.1 Fujirebio Corporation Information
11.5.2 Fujirebio Business Overview
11.5.3 Fujirebio Alzheimer's Disease Diagnosis Product Features and Attributes
11.5.4 Fujirebio Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.5.5 Fujirebio Alzheimer's Disease Diagnosis Revenue by Product in 2024
11.5.6 Fujirebio Alzheimer's Disease Diagnosis Revenue by Application in 2024
11.5.7 Fujirebio Alzheimer's Disease Diagnosis Revenue by Geographic Area in 2024
11.5.8 Fujirebio Alzheimer's Disease Diagnosis SWOT Analysis
11.5.9 Fujirebio Recent Developments
11.6 Diadem
11.6.1 Diadem Corporation Information
11.6.2 Diadem Business Overview
11.6.3 Diadem Alzheimer's Disease Diagnosis Product Features and Attributes
11.6.4 Diadem Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.6.5 Diadem Recent Developments
11.7 Labcorp
11.7.1 Labcorp Corporation Information
11.7.2 Labcorp Business Overview
11.7.3 Labcorp Alzheimer's Disease Diagnosis Product Features and Attributes
11.7.4 Labcorp Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.7.5 Labcorp Recent Developments
11.8 Neurocode
11.8.1 Neurocode Corporation Information
11.8.2 Neurocode Business Overview
11.8.3 Neurocode Alzheimer's Disease Diagnosis Product Features and Attributes
11.8.4 Neurocode Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.8.5 Neurocode Recent Developments
11.9 Cognitact
11.9.1 Cognitact Corporation Information
11.9.2 Cognitact Business Overview
11.9.3 Cognitact Alzheimer's Disease Diagnosis Product Features and Attributes
11.9.4 Cognitact Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.9.5 Cognitact Recent Developments
11.10 EUROIMMUN Medical Diagnostics
11.10.1 EUROIMMUN Medical Diagnostics Corporation Information
11.10.2 EUROIMMUN Medical Diagnostics Business Overview
11.10.3 EUROIMMUN Medical Diagnostics Alzheimer's Disease Diagnosis Product Features and Attributes
11.10.4 EUROIMMUN Medical Diagnostics Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Vazyme International
11.11.1 Vazyme International Corporation Information
11.11.2 Vazyme International Business Overview
11.11.3 Vazyme International Alzheimer's Disease Diagnosis Product Features and Attributes
11.11.4 Vazyme International Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.11.5 Vazyme International Recent Developments
11.12 KingMed Diagnostics
11.12.1 KingMed Diagnostics Corporation Information
11.12.2 KingMed Diagnostics Business Overview
11.12.3 KingMed Diagnostics Alzheimer's Disease Diagnosis Product Features and Attributes
11.12.4 KingMed Diagnostics Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.12.5 KingMed Diagnostics Recent Developments
11.13 Hoyotek
11.13.1 Hoyotek Corporation Information
11.13.2 Hoyotek Business Overview
11.13.3 Hoyotek Alzheimer's Disease Diagnosis Product Features and Attributes
11.13.4 Hoyotek Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.13.5 Hoyotek Recent Developments
11.14 Carrier Biomed
11.14.1 Carrier Biomed Corporation Information
11.14.2 Carrier Biomed Business Overview
11.14.3 Carrier Biomed Alzheimer's Disease Diagnosis Product Features and Attributes
11.14.4 Carrier Biomed Alzheimer's Disease Diagnosis Revenue and Gross Margin (2020-2025)
11.14.5 Carrier Biomed Recent Developments
12 Alzheimer's Disease DiagnosisIndustry Chain Analysis
12.1 Alzheimer's Disease Diagnosis Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Alzheimer's Disease Diagnosis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Alzheimer's Disease Diagnosis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Alzheimer's Disease Diagnosis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Alzheimer's Disease Diagnosis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Alzheimer's Disease Diagnosis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Alzheimer's Disease Diagnosis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Alzheimer's Disease Diagnosis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Alzheimer's Disease Diagnosis Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Alzheimer's Disease Diagnosis Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Alzheimer's Disease Diagnosis by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alzheimer's Disease Diagnosis as of 2024)
Table 11. Global Alzheimer's Disease Diagnosis Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Alzheimer's Disease Diagnosis Companies Headquarters
Table 13. Global Alzheimer's Disease Diagnosis Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Alzheimer's Disease Diagnosis Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Alzheimer's Disease Diagnosis Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Alzheimer's Disease Diagnosis Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Alzheimer's Disease Diagnosis Revenue by Application (2026-2031) & (US$ Million)
Table 21. Alzheimer's Disease Diagnosis High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Alzheimer's Disease Diagnosis Growth Accelerators and Market Barriers
Table 25. North America Alzheimer's Disease Diagnosis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Alzheimer's Disease Diagnosis Growth Accelerators and Market Barriers
Table 27. Europe Alzheimer's Disease Diagnosis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Alzheimer's Disease Diagnosis Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Alzheimer's Disease Diagnosis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Alzheimer's Disease Diagnosis Investment Opportunities and Key Challenges
Table 31. Central and South America Alzheimer's Disease Diagnosis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Alzheimer's Disease Diagnosis Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Alzheimer's Disease Diagnosis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche Alzheimer's Disease Diagnosis SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Quanterix Corporation Information
Table 44. Quanterix Description and Major Businesses
Table 45. Quanterix Product Features and Attributes
Table 46. Quanterix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Quanterix Revenue Proportion by Product in 2024
Table 48. Quanterix Revenue Proportion by Application in 2024
Table 49. Quanterix Revenue Proportion by Geographic Area in 2024
Table 50. Quanterix Alzheimer's Disease Diagnosis SWOT Analysis
Table 51. Quanterix Recent Developments
Table 52. Quest Diagnostics Corporation Information
Table 53. Quest Diagnostics Description and Major Businesses
Table 54. Quest Diagnostics Product Features and Attributes
Table 55. Quest Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Quest Diagnostics Revenue Proportion by Product in 2024
Table 57. Quest Diagnostics Revenue Proportion by Application in 2024
Table 58. Quest Diagnostics Revenue Proportion by Geographic Area in 2024
Table 59. Quest Diagnostics Alzheimer's Disease Diagnosis SWOT Analysis
Table 60. Quest Diagnostics Recent Developments
Table 61. C₂N Diagnostics Corporation Information
Table 62. C₂N Diagnostics Description and Major Businesses
Table 63. C₂N Diagnostics Product Features and Attributes
Table 64. C₂N Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. C₂N Diagnostics Revenue Proportion by Product in 2024
Table 66. C₂N Diagnostics Revenue Proportion by Application in 2024
Table 67. C₂N Diagnostics Revenue Proportion by Geographic Area in 2024
Table 68. C₂N Diagnostics Alzheimer's Disease Diagnosis SWOT Analysis
Table 69. C₂N Diagnostics Recent Developments
Table 70. Fujirebio Corporation Information
Table 71. Fujirebio Description and Major Businesses
Table 72. Fujirebio Product Features and Attributes
Table 73. Fujirebio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Fujirebio Revenue Proportion by Product in 2024
Table 75. Fujirebio Revenue Proportion by Application in 2024
Table 76. Fujirebio Revenue Proportion by Geographic Area in 2024
Table 77. Fujirebio Alzheimer's Disease Diagnosis SWOT Analysis
Table 78. Fujirebio Recent Developments
Table 79. Diadem Corporation Information
Table 80. Diadem Description and Major Businesses
Table 81. Diadem Product Features and Attributes
Table 82. Diadem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Diadem Recent Developments
Table 84. Labcorp Corporation Information
Table 85. Labcorp Description and Major Businesses
Table 86. Labcorp Product Features and Attributes
Table 87. Labcorp Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Labcorp Recent Developments
Table 89. Neurocode Corporation Information
Table 90. Neurocode Description and Major Businesses
Table 91. Neurocode Product Features and Attributes
Table 92. Neurocode Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Neurocode Recent Developments
Table 94. Cognitact Corporation Information
Table 95. Cognitact Description and Major Businesses
Table 96. Cognitact Product Features and Attributes
Table 97. Cognitact Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Cognitact Recent Developments
Table 99. EUROIMMUN Medical Diagnostics Corporation Information
Table 100. EUROIMMUN Medical Diagnostics Description and Major Businesses
Table 101. EUROIMMUN Medical Diagnostics Product Features and Attributes
Table 102. EUROIMMUN Medical Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. EUROIMMUN Medical Diagnostics Recent Developments
Table 104. Vazyme International Corporation Information
Table 105. Vazyme International Description and Major Businesses
Table 106. Vazyme International Product Features and Attributes
Table 107. Vazyme International Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Vazyme International Recent Developments
Table 109. KingMed Diagnostics Corporation Information
Table 110. KingMed Diagnostics Description and Major Businesses
Table 111. KingMed Diagnostics Product Features and Attributes
Table 112. KingMed Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. KingMed Diagnostics Recent Developments
Table 114. Hoyotek Corporation Information
Table 115. Hoyotek Description and Major Businesses
Table 116. Hoyotek Product Features and Attributes
Table 117. Hoyotek Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Hoyotek Recent Developments
Table 119. Carrier Biomed Corporation Information
Table 120. Carrier Biomed Description and Major Businesses
Table 121. Carrier Biomed Product Features and Attributes
Table 122. Carrier Biomed Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Carrier Biomed Recent Developments
Table 124. Raw Materials Key Suppliers
Table 125. Distributors List
Table 126. Market Trends and Market Evolution
Table 127. Market Drivers and Opportunities
Table 128. Market Challenges, Risks, and Restraints
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Alzheimer's Disease Diagnosis Product Picture
Figure 2. Global Alzheimer's Disease Diagnosis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Neuroimaging Examination Product Picture
Figure 4. Cerebrospinal Fluid Examination Product Picture
Figure 5. Peripheral Blood Antibody Examination Product Picture
Figure 6. Others Product Picture
Figure 7. Global Alzheimer's Disease Diagnosis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Clinical Diagnosis
Figure 9. Research
Figure 10. Alzheimer's Disease Diagnosis Report Years Considered
Figure 11. Global Alzheimer's Disease Diagnosis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 13. Global Alzheimer's Disease Diagnosis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Alzheimer's Disease Diagnosis Revenue Market Share by Region (2020-2031)
Figure 15. Global Alzheimer's Disease Diagnosis Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Neuroimaging Examination Revenue Market Share by Player in 2024
Figure 18. Cerebrospinal Fluid Examination Revenue Market Share by Player in 2024
Figure 19. Peripheral Blood Antibody Examination Revenue Market Share by Player in 2024
Figure 20. Others Revenue Market Share by Player in 2024
Figure 21. Global Alzheimer's Disease Diagnosis Revenue Market Share by Type (2020-2031)
Figure 22. Global Alzheimer's Disease Diagnosis Revenue Market Share by Application (2020-2031)
Figure 23. North America Alzheimer's Disease Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players Alzheimer's Disease Diagnosis Revenue (US$ Million) in 2024
Figure 25. North America Alzheimer's Disease Diagnosis Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America Alzheimer's Disease Diagnosis Revenue (US$ Million) by Application (2020-2031)
Figure 27. US Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 28. Canada Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 30. Europe Alzheimer's Disease Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players Alzheimer's Disease Diagnosis Revenue (US$ Million) in 2024
Figure 32. Europe Alzheimer's Disease Diagnosis Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe Alzheimer's Disease Diagnosis Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 35. France Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 37. Italy Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 38. Russia Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Alzheimer's Disease Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players Alzheimer's Disease Diagnosis Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific Alzheimer's Disease Diagnosis Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific Alzheimer's Disease Diagnosis Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 44. Japan Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 46. Australia Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 47. India Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore Alzheimer's Disease Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America Alzheimer's Disease Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players Alzheimer's Disease Diagnosis Revenue (US$ Million) in 2024
Figure 55. Central and South America Alzheimer's Disease Diagnosis Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America Alzheimer's Disease Diagnosis Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil Alzheimer's Disease Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina Alzheimer's Disease Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa Alzheimer's Disease Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players Alzheimer's Disease Diagnosis Revenue (US$ Million) in 2024
Figure 61. South America Alzheimer's Disease Diagnosis Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa Alzheimer's Disease Diagnosis Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries Alzheimer's Disease Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 64. Israel Alzheimer's Disease Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt Alzheimer's Disease Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa Alzheimer's Disease Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 67. Alzheimer's Disease Diagnosis Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
